. Author manuscript; available in PMC: 2023 Mar 1.

Published in final edited form as: Am J Obstet Gynecol. 2021 Sep 10;226(3):335–346. doi: 10.1016/j.ajog.2021.09.002

Table 2.

Comparison of US and International Guidelines for Hepatitis B in Antiviral Prophylaxis in Pregnancy to Prevent Transmission

Professional Organization	Strength of Recommendations	Year of Recommendation	Treatment Criteria	Medication of Choice	Duration of Therapy
US Society for Maternal Fetal Medicine (SMFM)⁹⁸	Consider treatment	2016	Viral load >6–8 log₁₀ copies/mL (>5.2 log₁₀ IU/mL)	Tenofovir disoproxil fumarate (TDF) PO daily	≥28 weeks GA - delivery
American Association for the Study of Liver Diseases (AASLD)¹⁰¹*	Suggests treatment	2016	Viral load >200,000 IU/mL (5.3 log₁₀ IU/mL)	Tenofovir disoproxil fumarate (TDF) PO daily	Initiation at 28–32 weeks GA. No clear recommendation for when to stop
European Association for the Study of the Liver (EASL)¹⁰²	Recommends treatment	2017	Viral load >200,000 IU/mL or HBsAg levels >4 log₁₀ IU/mL	Tenofovir disoproxil fumarate (TDF) PO daily	24–28 weeks GA and continue for up to 12 weeks after delivery
World Health Organization (WHO)¹⁰³	Recommends treatment	2020	Viral load ≥200,000 IU/mL (≥5.3 log₁₀ IU/mL)	Tenofovir disoproxil fumarate (TDF) PO daily	28 weeks GA – at least until delivery.